Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

TRAF1 anticorps (AA 73-219)

L’anticorps anti-TRAF1 Monoclonal Souris est utilisé pour la détection de TRAF1 dans des échantillons de Humain. Il a été validé pour ELISA.
N° du produit ABIN7863795
639,45 €
Plus frais de livraison 40,00 € et TVA
Destination: France
Envoi sous 6 à 10 jours ouvrables

Aperçu rapide pour TRAF1 anticorps (AA 73-219) (ABIN7863795)

Antigène

Voir toutes TRAF1 Anticorps
TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivité

  • 84
  • 35
  • 19
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
Humain

Hôte

  • 48
  • 39
  • 1
Souris

Clonalité

  • 52
  • 36
Monoclonal

Conjugué

  • 47
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
Cet anticorp TRAF1 est non-conjugé

Application

  • 35
  • 28
  • 26
  • 18
  • 13
  • 13
  • 10
  • 5
  • 3
  • 3
  • 3
  • 1
ELISA

Clone

TRAF1-3299
  • Épitope

    • 32
    • 15
    • 8
    • 6
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 73-219

    Fonction

    TRAF1 (TNFR-Associated Factor 1) (Lymphomatoid Papulosis Marker) Antibody

    Specificité

    This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

    Purification

    200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G.

    Immunogène

    Recombinant fragment of human TRAF1 protein (around aa 73-219) (exact sequence is proprietary)

    Isotype

    IgG1, kappa
  • Indications d'application

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Concentration

    200 μg/mL

    Buffer

    Prepared in 10 mM PBS with 0.05 % BSA & 0.05 % azide.

    Agent conservateur

    Sodium azide

    Précaution d'utilisation

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Stock

    4 °C

    Stockage commentaire

    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C.Antibody is stable for 24 months. Non-hazardous. No MSDS required.
  • Antigène

    TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

    Autre désignation

    TRAF1

    Sujet

    EBI6, EBV induced protein 6, Epstein-Barr virus-induced protein 6, TNF receptor-associated factor 1, TRAF1

    HeLa or 293T cells. Hodgkin s Lymphoma (IHC).

    Poids moléculaire

    52kDa

    ID gène

    7185, 531251

    UniProt

    Q13077

    Pathways

    Signalisation NF-kappaB, Apoptose, Cell-Cell Junction Organization, Asymmetric Protein Localization
Vous êtes ici:
Chat with us!